Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies

Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies

Androgen receptor (AR) variants (AR-Vs) expressed in prostate cancer (PCa) lack the AR ligand binding domain (LBD) and function as constitutively active transcription factors. AR-V expression in patient tissues or circulating tumor cells is associated with resistance to AR-targeting endocrine therap...

Full description

Bibliographic Details
Main Authors: Chan, Siu Chiu, Selth, Luke A., Li, Yingming, Nyquist, Michael D., Miao, Lu, Bradner, James E., Raj, Ganesh V., Tilley, Wayne D., Dehm, Scott M.
Format: Online
Language:English
Published: Oxford University Press 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499120/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499120/

Similar Items